IMD-3-1497 © 2005
Yaziji, Michael; Lindblom, Anna
The B- part of the cases concentrates on the result of the claim versus the South African federal government. The needs from the NGOs keep on coming and Garnier; the CEO of GSK; is faced with some difficult choices to make. Should he enable licensing? How should he handle parallel importation?
Subjects: NGOs; Non-market competition; Ethics;Pharmaceutical; AIDS;Patents
Settings: South Africa; Pharmaceutical; Largest pharmaceutical company in the world; >100;000 employees; 2001 - 2004
Related Case Solutions & Analyses:
D2Hawkeye: Growing the Medical IT Enterprise
AXMONY
Hertz Corporation (A)
Jay Nielson & AKKInternational: Outsourcing in India
Bluewater Foods Corporation
Finding a CEO for the School District of Philadelphia: Searching for a Savior
Venture Capital at the Harvard Management Company in Historical Perspective
Biosensors International Group: Valuation and Impairment Testing of Intangibles
Company Valuation
Potato Bonds: Regulating Spurious Derivative Instruments
